Global Oncology Biomarkers Market Share 2024, Forecast To 2033
8 Mar, 2024
The oncology biomarkers market (8) rose from $13.68 billion in 2023 to $15.69 billion in 2024, with a CAGR of 14.7%, due to precision medicine. Growth is expected to $26.09 billion by 2028, with a CAGR of 13.6%, driven by next-gen sequencing. Trends include biomarker standardization and immunotherapy applications.
Global Oncology Biomarkers Market Key Driver
The rising demand for electric vehicles is fueling the vehicle conversion market. With sales of electric vehicles nearly doubling in recent years, there is a growing trend towards converting traditional vehicles to electric ones.
Get A Free Sample Of The Global Oncology Biomarkers Market ReportGlobal Oncology Biomarkers Market Segments
The oncology biomarkers market covered in this report is segmented –
1) Biomarker Type:Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers
2) Profiling Technologies:Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies
3) Cancer Type:Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types
4) Application:Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
5) End-User:Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories
By Geography: The countries covered in the oncology biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the oncology biomarkers market in 2023. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Oncology Biomarkers Industry Players
F Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Eli Lilly and Company; Merck KGaA; Siemens Healthcare GmbH; Becton Dickinson and Company; GE Healthcare Technologies Inc.; Eurofins Scientific SE; Agilent Technologies Inc.; Hologic Inc.; Illumina Inc.; Charles River Laboratories International Inc.; bioMerieux SA; Bio-Rad Laboratories Inc.; Bruker Corporation; QIAGEN NV; Exact Sciences Corporation; Sysmex Corporation; PerkinElmer Inc.; Leica Biosystems; Myriad Genetics Inc.; Guardant Health Inc.; Enzo Biochem Inc.; Biocartis Group NV; Bristol -Myers Squibb Company; Agendia Inc.; Epigenomics AG; OncoDNA SA.
Get The Full Global Oncology Biomarkers Market Report
Oncology Biomarkers Market Overview
Oncology biomarkers refer to the biological molecules in a patient's body that suggest the presence of cancer in the patient. Oncology biomarkers provide information about cancer in a person's body.